[CAS NO. 78110-38-0] Aztreonam
PRODUCTS SPECIFICATIONS [78110-38-0]
DESCRIPTION [78110-38-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 435.43 |
| Molecular Formula | C13H17N5O8S2 |
| SMILES | CC(C)(O/N=C(C1=CSC(N)=N1)\C(N[C@H]2[C@H](C)N(S(=O)(O)=O)C2=O)=O)C(O)=O |
5 Publications Citing Use of MCE
Summary
Aztreonam (SQ-26,776) is a synthetic monocyclic beta-lactam antibiotic , which has a very high affinity for penicillin-binding protein 3 (PBP-3).
IC50 & Target
|
β-lactam |
In Vitro
Aztreonam (SQ-26,776) is a synthetic monocyclic beta-lactam antibiotic (a monobactam), with the nucleus based on a simpler monobactam isolated from Chromobacterium violaceum. It was approved by the U.S. Food and Drug Administration in 1986. It is resistant to some beta-lactamases, but is inactivated by extended-spectrum beta-lactamases. Aztreonam has no useful activity against gram-positive or anaerobic microorganisms [1] . Aztreonam (SQ-26) is similar in action to penicillin. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidogly can crosslinking. It has a very high affinity for penicillin-binding protein 3 (PBP-3) and mild affinity for PBP-1a. Aztreonam (SQ-26) binds the penicillin-binding proteins of gram-positive and anaerobic bacteria very poorly and is largely ineffective against them. Aztreonam (SQ-26) is bactericidal but less so than some of the cephalosporins [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03376529 | Spero Therapeutics|Simbec Research|QPS |
Healthy Volunteers
|
November 10, 2017 | Phase 1 |
| NCT03158116 | UCSF Benioff Children´s Hospital Oakland|Gilead Sciences |
Tracheostomy Infection
|
July 1, 2017 | Phase 4 |
| NCT03696290 | University of Dundee|Gilead Sciences |
Bronchiectasis Adult
|
October 19, 2019 | Phase 2 |
| NCT01375049 | Gilead Sciences |
Cystic Fibrosis
|
August 2011 | Phase 2 |
| NCT01460836 | Novartis Pharmaceuticals|Novartis |
Cystic Fibrosis
|
April 2010 | |
| NCT00424190 | Forest Laboratories |
Bacterial Infections
|
February 2007 | Phase 3 |
| NCT01689207 | Pfizer |
Complicated Infection|Bacterial Infections
|
September 2012 | Phase 1 |
| NCT01499277 | Pfizer|Forest Laboratories |
Complicated Skin and Soft Tissue Infection
|
May 2012 | Phase 3 |
| NCT00423657 | Forest Laboratories |
Bacterial Infections
|
March 2007 | Phase 3 |
| NCT02276482 | Cubist Pharmaceuticals LLC |
Skin Diseases, Infectious|Skin Diseases, Bacterial
|
March 25, 2015 | Phase 3 |
| NCT00989807 | Gilead Sciences |
Cystic Fibrosis|Pseudomonas Aeruginosa
|
||
| NCT00757237 | Gilead Sciences|Chiltern International Inc.|ClinPhone, Inc.|Covance |
Cystic Fibrosis
|
August 2008 | Phase 3 |
| NCT03749226 | Hospital Universitari Joan XXIII de Tarragona. |
Ventilator Associated Pneumonia|Prevention|Respiratory Infection Other
|
March 19, 2019 | Phase 2|Phase 3 |
| NCT01400867 | Forest Laboratories|AstraZeneca |
Infections, Pediatrics
|
December 2011 | Phase 2|Phase 3 |
| NCT01055847 | Gilead Sciences|Salus Pharma, Inc. |
Cystic Fibrosis|CF|Lung Infection|Pseudomonas Aeruginosa
|
June 2003 | Phase 2 |
| NCT00633152 | Forest Laboratories |
Bacterial Infection
|
February 2008 | Phase 2 |
| NCT01984684 | Melinta Therapeutics, Inc. |
Skin and Subcutaneous Tissue Bacterial Infections|Skin Structures and Soft Tissue Infections
|
May 2014 | Phase 3 |
| NCT03867734 | University of Washington |
Gonorrhea of Pharynx|Gonorrhea
|
April 5, 2019 | Phase 2|Phase 3 |
| NCT02894684 | Liverpool Heart and Chest Hospital NHS Foundation Trust|University of Liverpool |
Cystic Fibrosis|Infection|Pseudomonas
|
January 2017 | Phase 4 |
| NCT01469364 | Duke University|Gilead Sciences |
Complication of Transplanted Lung
|
March 2013 | Phase 4 |
| NCT00499720 | Gilead Sciences |
Cystic Fibrosis|Pseudomonas Aeruginosa Airway Infection
|
||
| NCT01659866 | Northwestern University |
Infection
|
August 2012 | Phase 4 |
| NCT01811732 | Melinta Therapeutics, Inc. |
Skin and Subcutaneous Tissue Bacterial Infections
|
April 2013 | Phase 3 |
| NCT00228410 | Wyeth is now a wholly owned subsidiary of Pfizer |
Skin Diseases, Infectious
|
November 2002 | Phase 3 |
| NCT02202135 | Pfizer|Forest Laboratories |
Complicated Skin and Soft Tissue Infection
|
June 2014 | Phase 3 |
| NCT02730793 | Virginia Commonwealth University|Eastern Virginia Medical School |
Cystic Fibrosis
|
January 2017 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 114.83 mM ; Need ultrasonic)
H 2 O : 10 mg/mL ( 22.97 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2966 mL | 11.4829 mL | 22.9658 mL |
| 5 mM | 0.4593 mL | 2.2966 mL | 4.5932 mL |
| 10 mM | 0.2297 mL | 1.1483 mL | 2.2966 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 10 mg/mL (22.97 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution
References
Synonyms